Sign In
Buy BEAM
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026
Beam Therapeutics: Expected To Boost Pipeline Development Into 2023
05:05pm, Friday, 09'th Dec 2022
Beam Therapeutics announced the recruitment of its first BEACON trial patient in the middle of November 2022. BEAM's announcement was followed by Editas Medicine's declaration of positive safety and e
BEAM Up as FDA Lifts Clinical Hold on the IND for BEAM-201
12:48pm, Monday, 05'th Dec 2022
The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. Stock up.
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding a
Buy Beam Therapeutics For 2023
05:49am, Friday, 02'nd Dec 2022
Shares of Beam Therapeutics lost buying momentum in recent weeks. Gene-editing therapy stocks are out of favor.
Beam Therapeutics to Participate in Upcoming Investor Conferences
06:30am, Wednesday, 09'th Nov 2022
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man
Why Beam Therapeutics Stock Is Falling Today
12:17pm, Monday, 07'th Nov 2022
Beam's decision not to move forward with sickle cell treatment BEAM-102 isn't sitting well with investors today.
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Tops Revenue Estimates
09:03am, Monday, 07'th Nov 2022
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -20% and 51.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
10:14am, Thursday, 20'th Oct 2022
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St
Beam Therapeutics: Now Is Not The Right Time To Own
06:38pm, Thursday, 15'th Sep 2022
Today, we put mid-cap biotech concern Beam Therapeutics Inc. in the spotlight for the first time. Beam Therapeutics is advancing its pipeline on a wide front and the stock has had a nice ride over the
Why Beam Therapeutics Stock Rocketed Higher This Week
09:25am, Friday, 26'th Aug 2022
The biotech's share price has been on a wild ride in 2022.
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
01:34pm, Monday, 22'nd Aug 2022
This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 16, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.
A Comprehensive Guide to Genomic ETFs
12:03pm, Friday, 12'th Aug 2022
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
09:02am, Tuesday, 09'th Aug 2022
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
05:08pm, Wednesday, 03'rd Aug 2022
Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted t
Why Beam Therapeutics Stock Dipped Today
01:38pm, Monday, 01'st Aug 2022
A clinical hold is weighing on the biotech's shares today.
